-
Published in The Lancet | First-in-Class Bispecific ADC Iza-bren Reshapes Clinical Treatment Decision-Making and Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer
The 2026 ESMO Congress brought major advances to the forefront of oncology. Iza-bren (BL-B01D1/伦康依隆妥单抗), the world’s first-in-class and first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC), made a striking appearance with data from its pivotal Phase III PANKU-Breast01 study. The study presented its prespecified interim analysis results in full for the first time in a late-breaking…
-
ESMO Investigator Insights | Professor Qingyuan Zhang: Robust Clinical Evidence Demonstrates the Strength of Iza-bren, Ushering in a New Era of Breast Cancer Treatment
The European Society for Medical Oncology (ESMO) Congress is one of the most influential academic events in global oncology, where the presentation of each major study has the potential to reshape the clinical treatment landscape. Iza-bren (伦康依隆妥单抗), a globally pioneering, first-in-class bispecific antibody–drug conjugate (ADC) and the first of its kind to receive regulatory approval…
-
ESMO Investigator Insights | Professor Shusen Wang: Reshaping the Breast Cancer Treatment Landscape—How Iza-bren Is Ushering in a New Era of Bispecific ADC Therapy
The European Society for Medical Oncology (ESMO) Congress is one of the most prestigious academic events in global oncology, where the presentation of every major study has the potential to reshape the clinical treatment landscape. Iza-bren (伦康依隆妥单抗) is the world’s first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC). At this year’s congress, the pivotal Phase III…
-
ESMO Investigator Insights | Professor Yehui Shi: Confronting Challenges and Breaking New Ground—How the World’s First Bispecific ADC, Iza-bren, Is Ushering in a New Era of Bispecific ADC Therapy for Breast Cancer
The European Society for Medical Oncology (ESMO) Congress is one of the most highly anticipated academic events in global oncology, where the presentation of every major study has the potential to reshape the clinical treatment landscape. Iza-bren (BL-B01D1/伦康依隆妥单抗) is the world’s first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC). At this year’s congress, the pivotal Phase…
-
2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care
Against the vibrant autumn backdrop of Nanjing, breast cancer experts gathered on October 11, 2026, for the 2026 East China Breast Cancer Salon. Under the theme “Ninety Years of Compassion and Dedication, Passing the Torch of Medical Excellence,” the meeting focused on advances in breast cancer diagnosis and treatment, clinical implementation, and the development of…
-
ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy
With advances in clinical research and updates to treatment guidelines, antibody–drug conjugate (ADC) combinations with immunotherapy have become a new standard of first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). The 2026 Congress of the European Society for Medical Oncology (ESMO) will be held in Madrid, Spain, from October 23 to 27, local…
-
Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management
Prostate cancer is one of the most common malignancies threatening men’s health. In China, a high proportion of patients are diagnosed at the locally advanced or advanced stage, and overall outcomes continue to lag behind those in developed countries. Improving the overall effectiveness of prostate cancer treatment requires a systematic approach to standardizing and harmonizing…
-
SIBCS 2026 | Professor Jian Zhang: From Adjuvant CDK4/6 Inhibitors to Post-Recurrence Treatment—New Perspectives on Stratified Management of HR+/HER2− Advanced Breast Cancer
The 21st Shanghai International Breast Cancer Symposium (SIBCS) was held in Shanghai on October 16–17, 2026. The meeting brought together experts in breast cancer from across China for in-depth discussions on comprehensive breast cancer management and precision, stratified treatment.
Connecting Medical Expertise through Media